SAREPTA THERAPEUTICS, INC.

Lobbying for SAREPTA THERAPEUTICS, INC.

Filing 2nd Quarter - Report

Reporting period

2nd Quarter 2026

Apr 1 - June 30 · Posted Jul 20, 2026

Expenses

$220,000.00

What this organization spent lobbying with its own staff. Reported using A: the three LDA methods count different costs, so an expenses figure is not comparable across filers that used different ones.

Client based in

California

Official filing document

Government bodies contacted 2

HOUSE OF REPRESENTATIVES
SENATE

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when.

Bills named in this filing 2

HR 9260
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2027
HR 1509
Accelerating Kids’ Access to Care Act of 2025

Lobbying activity 4

Budget/Appropriations

H.R. 9260 - LHHS Appropriations

Health Issues

H.R. 1509 - Accelerating Kids Access to Care Act Patient Access Act Issues related to patient access to treatment

Science/Technology

National Security Commission on emerging biotechnology policy proposals

Trade (domestic/foreign)

Issues related to supply chain Issues related to Section 232

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.